Phase I clinical study of peptide vaccine using Cancer-Testis antigen against advanced esophageal cancer

Phase I clinical study of peptide vaccine using Cancer-Testis antigen against advanced esophageal cancer - CT antigen vaccine to advanced esophageal cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004006

Enrollment

Registered

2010-08-06

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced esophageal squamous cell carcinoma refractory to standard therapeutic modality

Interventions

Peptide vaccination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Performance status 0-2 (2Age 20 to 80 years-old (3)WBC<=2000,>=15000 PLT<=75000 GOT>=150 GPT>=150 T-bil>=2.0 Cr>=2.0 (4)HLA-A2402 positive (5)Obtains written informed concent

Exclusion criteria

Exclusion criteria: (1)Pregnant woman (2)Lactating woman (3)Severe bleeding tendency (4)Uncontrolled infection (5)Concomitant treatment with steroids (6)patients who are judged inappropriate for the entry into study by the investigator

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and adverse event.	—

Countries

Japan

Contacts

Public ContactSatoshi Yajima

Toho University School of Medicine Division of general and gastroenterological surgery, Department of Surgery (Omori)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026